{
    "nct_id": "NCT06646276",
    "official_title": "A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).",
    "inclusion_criteria": "* Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).\n* Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.\n* Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants have already received certain types of treatment for extensive stage small cell lung cancer\n* Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy\n* Other protocol-defined Inclusion/Exclusion criteria apply.",
    "miscellaneous_criteria": ""
}